Skip to main content
SpringerLink
Log in

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hindie E, Mesguich C, Bouabdallah K, Milpied N. Advanced Hodgkin's lymphoma: end-of-treatment FDG-PET should be maintained. Eur J Nucl Med Mol Imaging. 2017; doi:10.1007/s00259-017-3714-4.

  2. Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim Fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816. J Clin Oncol. 2016; doi:10.1200/JCO.2015.63.1119.

  3. Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374:2419–29. doi:10.1056/NEJMoa1510093.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016;34:1376–85. doi:10.1200/JCO.2015.63.0699.

    Article  CAS  PubMed  Google Scholar 

  5. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52. doi:10.1200/JCO.2007.11.6525.

    Article  CAS  PubMed  Google Scholar 

  6. Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99:1107–13. doi:10.3324/haematol.2013.103218.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, et al. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol. 2016;175:652–60. doi:10.1111/bjh.14292.

    Article  PubMed  Google Scholar 

  8. Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39:4–12. doi:10.1007/s00259-011-1916-8.

    Article  PubMed  Google Scholar 

  9. Adams HJ, Kwee TC. Predictive value of interim [18F]Fluorodeoxyglucose-positron emission tomography in advanced-stage Hodgkin lymphoma is not well established. J Clin Oncol. 2017;35:370–1. doi:10.1200/JCO.2016.68.1494.

    Article  PubMed  Google Scholar 

  10. Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin study group. Lancet Oncol. 2017;18:454–63. doi:10.1016/S1470-2045(17)30103-1.

    Article  CAS  PubMed  Google Scholar 

  11. Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, et al. Posttreatment PET/CT rather than interim PET/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET/CT with conventional imaging. J Nucl Med. 2017;58:577–83. doi:10.2967/jnumed.116.176511.

    Article  PubMed  Google Scholar 

  12. Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011;22:910–5. doi:10.1093/annonc/mdq549.

    Article  CAS  PubMed  Google Scholar 

  13. Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51:1337–43. doi:10.2967/jnumed.109.073197.

    Article  CAS  PubMed  Google Scholar 

  14. Filippi AR, Botticella A, Bello M, Botto B, Castiglione A, Gavarotti P, et al. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leuk. Lymphoma. 2013;54:1183–7. doi:10.3109/10428194.2012.735667.

    Article  CAS  PubMed  Google Scholar 

  15. Jalali A, Ha FJ, Chong G, Grigg A, McKendrick J, Schwarer AP, et al. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Ann Hematol. 2016;95:809–16. doi:10.1007/s00277-016-2611-4.

    Article  CAS  PubMed  Google Scholar 

  16. Lopci E, Burnelli R, Guerra L, Cistaro A, Piccardo A, Zucchetta P, et al. Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. Eur J Nucl Med Mol Imaging. 2011;38:1620–7. doi:10.1007/s00259-011-1836-7.

    Article  PubMed  Google Scholar 

  17. Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, et al. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk. Lymphoma. 2012;53:64–70. doi:10.3109/10428194.2011.603444.

    Article  CAS  PubMed  Google Scholar 

  18. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117:5314–20. doi:10.1182/blood-2010-10-314260.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Adams HJ, Kwee TC. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis. Eur J Radiol. 2016;85:1963–70. doi:10.1016/j.ejrad.2016.08.011.

    Article  PubMed  Google Scholar 

  20. Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol. 2002;55:162–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jakobsen LH, Hutchings M, de Nully Brown P, Linderoth J, Mylam KJ, Molin D, et al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. Br J Haematol. 2016;173:236–44. doi:10.1111/bjh.13943.

    Article  CAS  PubMed  Google Scholar 

  22. Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol. 2011;90:165–71. doi:10.1007/s00277-010-1044-8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology and Nuclear Medicine, Deventer Ziekenhuis, Nico Bolkesteinlaan 75, 7416 SE, Deventer, The Netherlands

    Hugo J. A. Adams

  2. Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    Thomas C. Kwee

Authors
  1. Hugo J. A. Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas C. Kwee
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Hugo J.A. Adams: study design, article writing, final approval of the manuscript.

Thomas C. Kwee: study design, article writing, final approval of the manuscript.

Corresponding author

Correspondence to Hugo J. A. Adams.

Ethics declarations

Conflicts of interest

None.

Funding

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adams, H.J.A., Kwee, T.C. Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 44, 1934–1936 (2017). https://doi.org/10.1007/s00259-017-3771-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3771-8

Search

Navigation